Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Banting Postdoctoral Fellowship Program

University of Toronto

$140,000.00

Patient specific Kidney-on-a-Chip technology in 96-well plate format defines an ex vivo system for personalized drug testing

FY 2016-17

Summary
The kidney has a primary function of filtering and eliminating 20-25% of ingested drugs and is highly susceptible to injury from drugs. Up to 20% of acute kidney injury acquired after hospital admissions is attributable to drug induced injury. Therefore the kidney is a major organ to consider in evaluating safety during drug development as well as for fine-tuning patient dosage during administration. Screening with engineered human kidney tissues (Kidney-on-a-Chip) that has organ-level function will complement the traditional cell-based screening and animal pre-clinical trial. When populating a Kidney-on-a-Chip platform with patient-specific kidney tissues, there is also a potential of fine-tuning drug dosage for individual patient before administration, facilitating a personalized medicine approach. Various Organ-on-a-Chip models, including heart, liver, lung, and gut, have been developed, but the Kidney-on-a-Chip model is still a nascent field and a challenging model to build due to complexity of the kidney vascular system. Our previous advances in the AngioChip technology successfully incorporated blood vessel networks into Heart-on-a-Chip and Liver-on-a-Chip models, a vital breakthrough as drugs are often delivered through the blood circulation system. To take this technology to the next step, we propose to develop a patient specific Kidney-on-a-Chip model upgraded with micro blood vessel networks and placed in a user-friendly multi-well plate design. Complete kidney nephrons (the functional units of kidney) isolated from primary patient biopsy will be cultured under perfusion on an engineered vascular bed. On the platform we will be able to examine patient specific drug toxicity, mechanisms of kidney disease and potential treatment directly on the patient specific kidney tissue in real time. Building on our previous advances and clinical expertise, we are well positioned to improve the quality of life for Canadians with safer and more effective drugs.
Program
Banting Postdoctoral Fellowship Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
358948
Name
Zhang Boyang
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Patient specific Kidney-on-a-Chip technology in 96-well plate format defines an ex vivo system for personalized drug testing
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Kidney; Organ-On-A-Chip
Abstract
The kidney has a primary function of filtering and eliminating 20-25% of ingested drugs and is highly susceptible to injury from drugs. Up to 20% of acute kidney injury acquired after hospital admissions is attributable to drug induced injury. Therefore the kidney is a major organ to consider in evaluating safety during drug development as well as for fine-tuning patient dosage during administration. Screening with engineered human kidney tissues (Kidney-on-a-Chip) that has organ-level function will complement the traditional cell-based screening and animal pre-clinical trial. When populating a Kidney-on-a-Chip platform with patient-specific kidney tissues, there is also a potential of fine-tuning drug dosage for individual patient before administration, facilitating a personalized medicine approach. Various Organ-on-a-Chip models, including heart, liver, lung, and gut, have been developed, but the Kidney-on-a-Chip model is still a nascent field and a challenging model to build due to complexity of the kidney vascular system. Our previous advances in the AngioChip technology successfully incorporated blood vessel networks into Heart-on-a-Chip and Liver-on-a-Chip models, a vital breakthrough as drugs are often delivered through the blood circulation system. To take this technology to the next step, we propose to develop a patient specific Kidney-on-a-Chip model upgraded with micro blood vessel networks and placed in a user-friendly multi-well plate design. Complete kidney nephrons (the functional units of kidney) isolated from primary patient biopsy will be cultured under perfusion on an engineered vascular bed. On the platform we will be able to examine patient specific drug toxicity, mechanisms of kidney disease and potential treatment directly on the patient specific kidney tissue in real time. Building on our previous advances and clinical expertise, we are well positioned to improve the quality of life for Canadians with safer and more effective drugs.
Competitiondate
201609
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Zhang, Boyang
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~